

<!-- DFS Xcelerate Instance Document - http://www.dfsco.com/financial-services/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 1 -->
<!-- Creation date: 2018-10-31T14:30:50Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:galt="http://www.galectintherapeutics.com/20180930" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="galt-20180930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <galt:FairValueOfAssetContributedToJointVenture contextRef="eol_PE87402---1810-Q0006_STD_0_20140131_0_1779175x1900661_1784321x1784953_1784583x1960983" unitRef="iso4217_USD" decimals="0" id="id_10451842_D2D946C9-7609-42FB-8998-E61309A66791_3003_1">400000</galt:FairValueOfAssetContributedToJointVenture>
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="eol_PE87402---1810-Q0006_STD_0_20140131_0_1784583x1960983" unitRef="pure" decimals="INF" id="id_10451842_D2D946C9-7609-42FB-8998-E61309A66791_4003_3">0.500</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE87402---1810-Q0006_STD_0_20170228_0_1781320x1923965" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10451842_F0B181C9-BA97-4A36-BA0D-413A148F7ED8_4001_3">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:SharePrice contextRef="eol_PE87402---1810-Q0006_STD_0_20170228_0_1781320x1923965" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10451842_F0B181C9-BA97-4A36-BA0D-413A148F7ED8_4001_5">1.86</us-gaap:SharePrice>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="eol_PE87402---1810-Q0006_STD_0_20170228_0_1781320x1923965_1787544x1787453" id="id_10451842_F0B181C9-BA97-4A36-BA0D-413A148F7ED8_5001_6">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <galt:AggregateOfferingPrice contextRef="eol_PE87402---1810-Q0006_STD_0_20170519_0_1794413x1925863" unitRef="iso4217_USD" decimals="-5" id="id_10451842_00C0B498-91B5-4107-BCF2-015B4331D332_1001_0">30000000</galt:AggregateOfferingPrice>
  <galt:CommissionsAsPercentageOfGrossOfferingProceeds contextRef="eol_PE87402---1810-Q0006_STD_0_20170519_0_1794413x1925863" unitRef="pure" decimals="3" id="id_10451842_00C0B498-91B5-4107-BCF2-015B4331D332_1001_1">0.030</galt:CommissionsAsPercentageOfGrossOfferingProceeds>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE87402---1810-Q0006_STD_0_20171219_0_1779182x1962572_1793148x1780634" unitRef="pure" decimals="4" id="id_10451842_9CE23B96-15DA-4538-AD88-8C46E5A9E617_1001_2">0.0151</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE87402---1810-Q0006_STD_0_20171219_0_1779182x1962572_1793148x1780634" unitRef="iso4217_USD" decimals="-6" id="id_10451842_9CE23B96-15DA-4538-AD88-8C46E5A9E617_1001_0">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20181107_0" unitRef="shares" decimals="INF" id="id_10451842_D49EEED2-E245-4DBF-99D5-A0DA428BC252_2_5">41136738</dei:EntityCommonStockSharesOutstanding>
  <galt:AggregateOfferingPrice contextRef="eol_PE87402---1810-Q0006_STD_0_20140330_0_1794413x1949985" unitRef="iso4217_USD" decimals="-5" id="id_10451842_8F8FE83D-9633-4D4B-8F94-ECAD8A7A28ED_1001_0">30000000</galt:AggregateOfferingPrice>
  <galt:CommissionsAsPercentageOfGrossOfferingProceeds contextRef="eol_PE87402---1810-Q0006_STD_0_20140330_0_1794413x1949985" unitRef="pure" decimals="3" id="id_10451842_8F8FE83D-9633-4D4B-8F94-ECAD8A7A28ED_1001_1">0.030</galt:CommissionsAsPercentageOfGrossOfferingProceeds>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1810-Q0006_STD_0_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_1002_16">6958000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_9">171000</us-gaap:AccountsPayableCurrent>
  <us-gaap:Assets contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_6">10616000</us-gaap:Assets>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_3E0A4418-7531-4C27-840E-3BE0A93F498B_1001_3">1475000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_4">10530000</us-gaap:AssetsCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_3E0A4418-7531-4C27-840E-3BE0A93F498B_1001_0">91000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_51">192843000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_381ECD02-6159-4097-A86D-9B9D079E281D_1_0">10136000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_14" />
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_48">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_50">41136738</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="shares" decimals="0" id="id_10451842_EF3EDCB7-CCDA-4EB3-A876-34C1967DBD21_2001_0">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_47">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_49">41136738</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_46">41000</us-gaap:CommonStockValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="0" id="id_10451842_BF3970BF-26C5-4CCA-A5BB-0F3E4069BA81_3001_0">1166000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_3E0A4418-7531-4C27-840E-3BE0A93F498B_1001_1">1005000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:Liabilities contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_13">1646000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_54">10616000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_12">1646000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_5">86000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_3">394000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="shares" decimals="INF" id="id_10451842_BF3970BF-26C5-4CCA-A5BB-0F3E4069BA81_3001_1">846893</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_52">-192866000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="shares" decimals="INF" id="id_10451842_1C7720C1-5B64-465A-9064-A98B68D1851E_3001_6">3764648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_87F52533-3AE8-449A-99A0-6F7ECF440ABA_3001_6">5.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_53">7247000</us-gaap:StockholdersEquity>
  <galt:UndesignatedCapitalStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_22">0</galt:UndesignatedCapitalStockValue>
  <galt:UndesignatedCapitalStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_25">20000000</galt:UndesignatedCapitalStockSharesOutstanding>
  <galt:UndesignatedCapitalStockSharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_24">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
  <galt:UndesignatedCapitalStockParValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1_23">0.01</galt:UndesignatedCapitalStockParValue>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1779182x1962572_1793148x1780634" unitRef="iso4217_USD_per_shares" decimals="0" id="id_10451842_9CE23B96-15DA-4538-AD88-8C46E5A9E617_1003_4">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1779182x1962572_1793148x1780634" unitRef="shares" decimals="-6" id="id_10451842_9CE23B96-15DA-4538-AD88-8C46E5A9E617_1003_3">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:LinesOfCreditCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1779182x1962572_1793148x1780634" unitRef="iso4217_USD" decimals="INF" id="id_10451842_9CE23B96-15DA-4538-AD88-8C46E5A9E617_1003_5">0</us-gaap:LinesOfCreditCurrent>
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1784583x1960983" unitRef="pure" decimals="3" id="id_10451842_D2D946C9-7609-42FB-8998-E61309A66791_4001_3">0.805</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <us-gaap:CommonStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1791038x1786251_1791654x1929454_1794413x1962765" unitRef="iso4217_USD" decimals="0" id="id_10451842_91C9D61B-024D-4EF4-9C3B-BA44281C6BEA_3001_0">100000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1791654x1929454_1794413x1962765" unitRef="shares" decimals="INF" id="id_10451842_91C9D61B-024D-4EF4-9C3B-BA44281C6BEA_4001_1">2883</us-gaap:CommonStockSharesIssued>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1791539" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1001_15">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1791539" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1001_17">176</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1791539" unitRef="iso4217_USD" decimals="0" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1001_19">7956000</us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1791539" unitRef="iso4217_USD" decimals="0" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1001_20">1760000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1791539" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1001_18">176</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1791539" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1001_16">1000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1909376" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2001_44">2508000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1909376" unitRef="iso4217_USD" decimals="0" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2001_45">2508000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1909376" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2001_42">2508000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1909376" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2001_41">1224000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1909376" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2001_43">2508000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1953652" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_3001_29">1352500</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1953652" unitRef="iso4217_USD" decimals="0" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_3001_30">1352500</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1953652" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_3001_27">1742500</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1953652" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_3001_26">547000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1953652" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_3001_28">1352500</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1957907" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_4001_34">900000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1957907" unitRef="iso4217_USD" decimals="0" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_4001_35">1800000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1957907" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_4001_32">900000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1957907" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_4001_31">1761000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1957907" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_4001_33">900000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1962989" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_5001_39">2100000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1962989" unitRef="iso4217_USD" decimals="0" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_5001_40">4200000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1962989" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_5001_37">2100000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1962989" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_5001_36">3697000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1962989" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_5001_38">2100000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792342x1795345" unitRef="shares" decimals="INF" id="id_10451842_22534239-6A3C-4EE4-BA88-CD6A8020F8AB_4001_6">10697026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792342x1795345" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_3F938FF9-B8A8-4A83-9B33-0082CBADF506_4001_6">3.54</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1810-Q0006_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_2001_15">15362000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_9">608000</us-gaap:AccountsPayableCurrent>
  <us-gaap:Assets contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_6">4161000</us-gaap:Assets>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_3E0A4418-7531-4C27-840E-3BE0A93F498B_1002_3">2292000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_4">3819000</us-gaap:AssetsCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_3E0A4418-7531-4C27-840E-3BE0A93F498B_1002_0">74000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_51">173363000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_2">3053000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_14" />
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_48">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_50">35789388</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_47">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_49">35789388</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_46">36000</us-gaap:CommonStockValue>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_3E0A4418-7531-4C27-840E-3BE0A93F498B_1002_1">790000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:DividendsPayableCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_11">68000</us-gaap:DividendsPayableCurrent>
  <us-gaap:Liabilities contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_13">2968000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_54">4161000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_12">2968000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_5">342000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_3">766000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_52">-181168000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_10451842_1C7720C1-5B64-465A-9064-A98B68D1851E_1001_2">5155263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_87F52533-3AE8-449A-99A0-6F7ECF440ABA_1001_2">4.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_53">-530000</us-gaap:StockholdersEquity>
  <galt:UndesignatedCapitalStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_22">0</galt:UndesignatedCapitalStockValue>
  <galt:UndesignatedCapitalStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_25">20000000</galt:UndesignatedCapitalStockSharesOutstanding>
  <galt:UndesignatedCapitalStockSharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_24">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
  <galt:UndesignatedCapitalStockParValue contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2_23">0.01</galt:UndesignatedCapitalStockParValue>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1791539" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1002_15">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1791539" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1002_17">176</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1791539" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1002_18">176</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1791539" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_1002_16">1000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1909376" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2002_44">2508000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1909376" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2002_42">2508000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1909376" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2002_41">1224000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1909376" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_2002_43">2508000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1953652" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_3002_29">1377500</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1953652" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_3002_27">1742500</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1953652" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_3002_26">557000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1953652" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_3002_28">1377500</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1957907" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_4002_34">900000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1957907" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_4002_32">900000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1957907" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_4002_31">1761000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1957907" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_4002_33">900000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1962989" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_5002_39">2100000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1962989" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_5002_37">2100000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1962989" unitRef="iso4217_USD" decimals="-3" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_5002_36">3697000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1962989" unitRef="shares" decimals="INF" id="id_10451842_48593313-D42E-4132-B333-C9FB5E8E4B59_5002_38">2100000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792342x1795345" unitRef="shares" decimals="INF" id="id_10451842_22534239-6A3C-4EE4-BA88-CD6A8020F8AB_1001_2">13229778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792342x1795345" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_3F938FF9-B8A8-4A83-9B33-0082CBADF506_1001_2">3.35</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="eol_PE87402---1810-Q0006_STD_0_20171231_0_1793148x1780634" unitRef="pure" decimals="2" id="id_10451842_9CE23B96-15DA-4538-AD88-8C46E5A9E617_2002_1">0.07</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE87402---1810-Q0006_STD_1_20170228_0_1781320x1923965" unitRef="iso4217_USD" decimals="0" id="id_10451842_F0B181C9-BA97-4A36-BA0D-413A148F7ED8_1001_1">200000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="eol_PE87402---1810-Q0006_STD_1_20170228_0_1781320x1923965" unitRef="iso4217_USD" decimals="INF" id="id_10451842_F0B181C9-BA97-4A36-BA0D-413A148F7ED8_1001_4">101000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE87402---1810-Q0006_STD_1_20170228_0_1781320x1923965" unitRef="shares" decimals="INF" id="id_10451842_F0B181C9-BA97-4A36-BA0D-413A148F7ED8_1001_0">102368</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <galt:ClassOfWarrantOrRightIssuedInPeriod contextRef="eol_PE87402---1810-Q0006_STD_1_20170228_0_1781320x1923965" unitRef="shares" decimals="INF" id="id_10451842_F0B181C9-BA97-4A36-BA0D-413A148F7ED8_1001_2">76776</galt:ClassOfWarrantOrRightIssuedInPeriod>
  <galt:WarrantsAndRightsOutstandingMeasurementInputPercentage contextRef="eol_PE87402---1810-Q0006_STD_1_20170228_0_1781320x1923965_1787544x1787543" unitRef="pure" decimals="2" id="id_10451842_F0B181C9-BA97-4A36-BA0D-413A148F7ED8_2001_7">0.97</galt:WarrantsAndRightsOutstandingMeasurementInputPercentage>
  <galt:WarrantsAndRightsOutstandingMeasurementInputPercentage contextRef="eol_PE87402---1810-Q0006_STD_1_20170228_0_1781320x1923965_1787544x1788637" unitRef="pure" decimals="4" id="id_10451842_F0B181C9-BA97-4A36-BA0D-413A148F7ED8_3001_8">0.0192</galt:WarrantsAndRightsOutstandingMeasurementInputPercentage>
  <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="eol_PE87402---1810-Q0006_STD_1369_20180930_0_1779175x1900661_1784583x1960983" unitRef="iso4217_USD" decimals="0" id="id_10451842_D2D946C9-7609-42FB-8998-E61309A66791_1001_4">123000</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
  <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="eol_PE87402---1810-Q0006_STD_1369_20180930_0_1784583x1960983" unitRef="iso4217_USD" decimals="0" id="id_10451842_D2D946C9-7609-42FB-8998-E61309A66791_2001_2">1756000</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE87402---1810-Q0006_STD_23_20180531_0" unitRef="shares" decimals="INF" id="id_10451842_BF3970BF-26C5-4CCA-A5BB-0F3E4069BA81_5_4">506875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="eol_PE87402---1810-Q0006_STD_23_20180531_0" unitRef="shares" decimals="INF" id="id_10451842_BF3970BF-26C5-4CCA-A5BB-0F3E4069BA81_5_5">115000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="eol_PE87402---1810-Q0006_STD_23_20180531_0_1794693x1912783" unitRef="shares" decimals="INF" id="id_10451842_BF3970BF-26C5-4CCA-A5BB-0F3E4069BA81_2005_6">391875</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="shares" decimals="0" id="id_10451842_22EC2E5D-5234-443A-AD8E-AF0FED173F56_2_3">21218760</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_2_14">-8404000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_4_12">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_2_3">1000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_2_9">629000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_4_2">3155000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_4_6">21000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_2_8">-379000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_2_5">27000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_2_13">3584000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_4_11">-14680000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_4_8">21000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_4_3">13874000</us-gaap:OperatingExpenses>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_2_10">-11988000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_4_9">-13853000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_4_4">-13874000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_4_10">827000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_2_12">3584000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_4_1">10719000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_73EBD41D-67AD-49F0-AFF0-582E2B986971_4_2">829000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="shares" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_4_13">34600000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <galt:SupplementalDividendsOnConvertiblePreferredStock contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_2_18">894000</galt:SupplementalDividendsOnConvertiblePreferredStock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0_1776205x1782641" unitRef="shares" decimals="0" id="id_10451842_22EC2E5D-5234-443A-AD8E-AF0FED173F56_1002_1">4656888</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0_1776205x1792354" unitRef="shares" decimals="0" id="id_10451842_22EC2E5D-5234-443A-AD8E-AF0FED173F56_2002_2">4312282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0_1776205x1795345" unitRef="shares" decimals="0" id="id_10451842_22EC2E5D-5234-443A-AD8E-AF0FED173F56_3002_0">12249590</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0_1784168x1782499" unitRef="iso4217_USD" decimals="-3" id="id_10451842_73EBD41D-67AD-49F0-AFF0-582E2B986971_1004_1">422000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_273_20170930_0_1784168x1792236" unitRef="iso4217_USD" decimals="-3" id="id_10451842_73EBD41D-67AD-49F0-AFF0-582E2B986971_2004_0">407000</us-gaap:ShareBasedCompensation>
  <dei:AmendmentFlag contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_3B33348E-6B36-4AF0-9549-DBFFB0E1F40E_1_1">false</dei:AmendmentFlag>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_AABEABE8-97E4-4DE7-9DFB-ADAE7703951E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;2. Accrued Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;September&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;(in thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Legal and accounting fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;790&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued research and development costs and other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;379&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,428&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,475&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,292&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="shares" decimals="0" id="id_10451842_22EC2E5D-5234-443A-AD8E-AF0FED173F56_1_3">18769789</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:BasisOfAccounting contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_CB0E1A66-0EBF-41EB-97AB-49052F23753F_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;1. Basis of Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Galectin Therapeutics Inc. (the &amp;#x201C;Company&amp;#x201D;) is a
 clinical stage biopharmaceutical company that is applying its
 leadership in galectin science and drug development to create new
 therapies for fibrotic disease, skin diseases and cancer. These
 candidates are based on the Company&amp;#x2019;s targeting of galectin
 proteins which are key mediators of biologic and pathologic
 functions. These compounds also may have application for drugs to
 treat other diseases and chronic health conditions.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The unaudited condensed consolidated financial statements as
 reported in this Quarterly Report on Form &lt;font style="white-space:nowrap"&gt;10-Q&lt;/font&gt; reflect all adjustments which are,
 in the opinion of management, necessary to present fairly the
 financial position of the Company as of September&amp;#xA0;30, 2018 and
 the results of its operations for the three and nine months ended
 September&amp;#xA0;30, 2018 and 2017 and its cash flows for the nine
 months ended September&amp;#xA0;30, 2018 and 2017. All adjustments made
 to the interim financial statements include all those of a normal
 and recurring nature. Amounts presented in the condensed
 consolidated balance sheet as of December&amp;#xA0;31, 2017 are derived
 from the Company&amp;#x2019;s audited consolidated financial statements
 as of that date, but do not include all of the information and
 footnotes required by accounting principles generally accepted in
 the United States of America for complete financial statements. The
 Company considers events or transactions that occur after the
 balance sheet date but before the financial statements are issued
 to provide additional evidence relative to certain estimates or to
 identify matters that require additional disclosure. Subsequent
 events have been evaluated through the date these financial
 statements are available to be issued. The results for interim
 periods are not necessarily indicative of results that may be
 expected for any other interim period or for the full year. The
 unaudited condensed consolidated financial statements of the
 Company should be read in conjunction with its Annual Report on
 Form &lt;font style="white-space:nowrap"&gt;10-K&lt;/font&gt; for the year
 ended December&amp;#xA0;31, 2017.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has operated at a loss since its inception and has had
 no significant revenues. The Company anticipates that losses will
 continue for the foreseeable future. At September&amp;#xA0;30, 2018,
 the Company had $10.1&amp;#xA0;million of unrestricted cash and cash
 equivalents available to fund future operations. The Company
 believes there is sufficient cash, including availability of the
 line of credit (discussed in Note 3 below), to fund currently
 planned operations at least through September&amp;#xA0;30, 2019. The
 Company&amp;#x2019;s ability to fund operations after its current cash
 resources are exhausted depends on its ability to obtain additional
 financing or achieve profitable operations, as to which no
 assurances can be given. Accordingly, based on the forecasts and
 estimates underlying the Company&amp;#x2019;s current operating plan,
 the financial statements do not currently include any adjustments
 that might be necessary if the Company is unable to continue as a
 going concern.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company was founded in July 2000, was incorporated in the State
 of Nevada in January 2001 under the name &lt;font style="white-space:nowrap"&gt;&amp;#x201C;Pro-Pharmaceuticals,&lt;/font&gt;
 Inc.,&amp;#x201D; and changed its name to &amp;#x201C;Galectin Therapeutics
 Inc.&amp;#x201D; on May&amp;#xA0;26, 2011.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccounting>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_1_14">7083000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_9D3EB49F-4FC7-4EE4-80A0-E5ADA5BC866E_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;9. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company records accruals for such contingencies to the extent
 that the Company concludes that their occurrence is probable, and
 the related damages are estimable. There are no other significant
 pending legal proceedings.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_D49EEED2-E245-4DBF-99D5-A0DA428BC252_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_0CE3A292-09A7-44F0-AE94-D2773848C6C7_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;3. Line of Credit&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On December&amp;#xA0;19, 2017, the Company entered into a
 $10&amp;#xA0;million Line of Credit arrangement with Richard E.
 Uihlein, a director and shareholder who has an approximate 7%
 ownership interest in the Company on a fully-diluted basis at
 December&amp;#xA0;31, 2017. Borrowings may be made by the Company
 through December&amp;#xA0;31, 2018. Borrowings bear interest at the
 Applicable Federal Rate for short term loans published by the
 Internal Revenue Service (1.51% on December&amp;#xA0;19, 2017). All
 borrowings and interest are due on December&amp;#xA0;31, 2019 but may
 be prepaid without penalty. In connection with the Line of Credit
 agreement, the Company issued to Mr.&amp;#xA0;Uihlein warrants to
 purchase 1&amp;#xA0;million shares of the Company&amp;#x2019;s common stock
 for $5 per share. Half of the warrants vested at closing of the
 Line of Credit and the other half vest ratably with borrowings
 under the agreement. There have been no borrowings under the Line
 of Credit through September&amp;#xA0;30, 2018.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The fair value of the 500,000 warrants vested at closing was
 $696,000 at the date of issuance based on the following
 assumptions: an expected life of 7 years, volatility of 98%, risk
 free interest rate of 2.05% and zero dividends. The fair value of
 the vested warrants was recorded in other current assets and other
 assets &lt;font style="white-space:nowrap"&gt;(non-current)&lt;/font&gt; as a
 deferred financing cost and will be amortized on a straight-line
 basis from December&amp;#xA0;19, 2017 through December&amp;#xA0;31, 2019.
 Amortization for the three and nine months ended September&amp;#xA0;30,
 2018 of $87,000 and $256,000, respectively, was recorded as
 interest expense. The fair value of warrants that vest in the
 future based on borrowings will be computed when those borrowings
 occur and amortized over the remaining period through
 December&amp;#xA0;31, 2019.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_3_12">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_BF25521F-DE70-4329-97CE-07E6AB3BF69E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;7. Loss Per Share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic net loss per common share is computed by dividing the net
 loss available to common stockholders by the weighted average
 number of common shares outstanding during the period. Diluted net
 loss per common share is computed by dividing the net loss
 available to common stockholders by the weighted average number of
 common shares and other potential common shares then outstanding.
 Potential common shares consist of common shares issuable upon the
 assumed exercise of &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;in-the-money&lt;/font&gt;&lt;/font&gt; stock options and
 warrants and potential common shares related to the conversion of
 the preferred stock. The computation of diluted net loss per share
 does not assume the issuance of common shares that have an
 anti-dilutive effect on net loss per share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Dilutive shares which could exist pursuant to the exercise of
 outstanding stock instruments and which were not included in the
 calculation because their affect would have been anti-dilutive are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;September&amp;#xA0;30,&lt;br /&gt;
 2018&lt;br /&gt;
 (shares)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;September&amp;#xA0;30,&lt;br /&gt;
 2017&lt;br /&gt;
 (shares)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrants to purchase shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,697,026&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,249,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options to purchase shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,764,648&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,656,888&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shares of common stock issuable upon conversion of preferred
 stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,308,115&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,312,282&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,769,789&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,218,760&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_F2641D07-D005-4F32-A62E-5D79733BF8FC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;4. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Following is the stock-based compensation expense related to common
 stock options, common stock, restricted common stock and common
 stock warrants:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;252&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;109&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,413&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;407&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;411&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,880&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;422&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;663&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;230&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,293&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;829&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the stock option activity in the
 Company&amp;#x2019;s equity incentive plans, including &lt;font style="WHITE-SPACE: nowrap"&gt;non-plan&lt;/font&gt; grants to Company executives,
 from December&amp;#xA0;31, 2017 through&amp;#xA0;September 30, 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,155,263&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,011,875&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.02&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,193,366&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.99&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(209,124&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, September&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,764,648&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of September&amp;#xA0;30, 2018, there was $1,166,000 of unrecognized
 compensation related to 846,893 unvested options, which is expected
 to be recognized over a weighted&amp;#x2013;average period of
 approximately 0.25 years. The weighted-average grant date fair
 value for options granted during the nine months ended
 September&amp;#xA0;30, 2018 was $3.98. The Company granted 460,000
 stock options in January 2018, of which 115,000 options vested upon
 grant with the remaining 345,000 options vesting over the remainder
 of 2018. Approximately $526,000 of &lt;font style="WHITE-SPACE: nowrap"&gt;non-cash,&lt;/font&gt; stock-based compensation
 expense was recorded during the three months ended March&amp;#xA0;31,
 2018 related to the options granted in January 2018 that vested
 upon the grant date. Additionally, Company granted 506,875 stock
 options during May 2018, of which 115,000 options vested upon grant
 with the remaining 391,875 options vesting over the remainder of
 2018. Approximately $433,000 of &lt;font style="WHITE-SPACE: nowrap"&gt;non-cash,&lt;/font&gt; stock-based compensation
 expense was recorded during the three months ended June&amp;#xA0;30,
 2018 related to the options granted in May 2018 that vested upon
 the grant date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of all other options granted is determined using the
 Black-Scholes option-pricing model. The following weighted average
 assumptions were used:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Nine&lt;br /&gt;
 Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Nine&lt;br /&gt;
 Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;br /&gt;
 2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.47&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life of the options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.7&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility of the underlying stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;104&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_3B33348E-6B36-4AF0-9549-DBFFB0E1F40E_1_4">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_3B33348E-6B36-4AF0-9549-DBFFB0E1F40E_1_3">2018</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_3B33348E-6B36-4AF0-9549-DBFFB0E1F40E_1_0">10-Q</dei:DocumentType>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_BF3970BF-26C5-4CCA-A5BB-0F3E4069BA81_1_2">P3M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <dei:EntityRegistrantName contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_D49EEED2-E245-4DBF-99D5-A0DA428BC252_1_1">GALECTIN THERAPEUTICS INC</dei:EntityRegistrantName>
  <dei:EntitySmallBusiness contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_D49EEED2-E245-4DBF-99D5-A0DA428BC252_1_7">true</dei:EntitySmallBusiness>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_6B107F34-A9C6-4B4A-8DD8-8871D84EDF79_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;6. Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 At times, the Company has certain financial assets and liabilities
 recorded at fair value. Fair values determined by Level&amp;#xA0;1
 inputs utilize observable data such as quoted prices in active
 markets. Fair values determined by Level&amp;#xA0;2 inputs utilize data
 points other than quoted prices in active markets that are
 observable either directly or indirectly. Fair values determined by
 Level&amp;#xA0;3 inputs utilize unobservable data points in which there
 is little or no market data, which require the reporting entity to
 develop its own assumptions. The carrying amounts reflected in the
 consolidated balance sheets for cash equivalents, accounts payable
 and accrued expenses approximate their carrying value due to their
 short-term nature. There were no level 2 or level 3 assets or
 liabilities at September&amp;#xA0;30, 2018 or December&amp;#xA0;31,
 2017.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <dei:EntityCentralIndexKey contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_D49EEED2-E245-4DBF-99D5-A0DA428BC252_1_2">0001133416</dei:EntityCentralIndexKey>
  <dei:DocumentPeriodEndDate contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_3B33348E-6B36-4AF0-9549-DBFFB0E1F40E_1_2">2018-09-30</dei:DocumentPeriodEndDate>
  <dei:EntityEmergingGrowthCompany contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_D49EEED2-E245-4DBF-99D5-A0DA428BC252_1_6">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityFilerCategory contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_D49EEED2-E245-4DBF-99D5-A0DA428BC252_1_4">Non-accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_1_9">-1254000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_3_2">5338000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_3_6">23000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_1_8">-372000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestExpense contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_3_7">256000</us-gaap:InterestExpense>
  <us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_1180DDED-A1A3-4250-ACCD-2F9B573F1498_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;10. Galectin Sciences LLC&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In January 2014, we created Galectin Sciences, LLC (the
 &amp;#x201C;LLC&amp;#x201D; or &amp;#x201C;Investee&amp;#x201D;), a collaborative joint
 venture &lt;font style="white-space:nowrap"&gt;co-owned&lt;/font&gt; by SBH
 Sciences, Inc. (&amp;#x201C;SBH&amp;#x201D;), to research and develop small
 organic molecule inhibitors of &lt;font style="white-space:nowrap"&gt;galectin-3&lt;/font&gt; for oral administration. The
 LLC was initially capitalized with a $400,000 cash investment to
 fund future research and development activities, which was provided
 by the Company, and specific &lt;font style="white-space:nowrap"&gt;in-process&lt;/font&gt; research and development
 (&amp;#x201C;IPR&amp;amp;D&amp;#x201D;) contributed by SBH.&amp;#xA0;The estimated
 fair value of the IPR&amp;amp;D contributed by SBH, on the date of
 contribution, was $400,000.&amp;#xA0;Initially, the Company and SBH
 each had a 50% equity ownership interest in the LLC, with neither
 party having control over the LLC.&amp;#xA0;Accordingly, from inception
 through the fourth quarter of 2014, the Company accounted for its
 investment in the LLC using the equity method of
 accounting.&amp;#xA0;Under the equity method of accounting, the
 Company&amp;#x2019;s investment was initially recorded at cost with
 subsequent adjustments to the carrying value to recognize
 additional investments in or distributions from the Investee, as
 well as the Company&amp;#x2019;s share of the Investee&amp;#x2019;s earnings,
 losses and/or changes in capital. The estimated fair value of the
 IPR&amp;amp;D contributed to the LLC was immediately expensed upon
 contribution as there was no alternative future use available at
 the point of contribution.&amp;#xA0;The operating agreement provides
 that if either party does not desire to contribute its equal share
 of funding required after the initial capitalization, then the
 other party, providing all of the funding, will have its ownership
 share increased in proportion to the total amount contributed from
 inception. In the fourth quarter of 2014, after the LLC had
 expended the $400,000 in cash, SBH decided not to contribute its
 share of the funding required. Since then, the Company has
 contributed a total of $1,756,000, including $34,000 for the three
 months ended September&amp;#xA0;30, 2018, for expenses of the LLC.
 Since the end of 2014, SBH has contributed $123,000 for expenses in
 the LLC. As of September&amp;#xA0;30, 2018, the Company&amp;#x2019;s
 ownership percentage in the LLC was 80.5%. The Company accounts for
 the interest in the LLC as a consolidated, less than wholly owned
 subsidiary. Because the LLC&amp;#x2019;s equity is immaterial, the value
 of the &lt;font style="white-space:nowrap"&gt;non-controlling&lt;/font&gt;
 interest is also deemed to be immaterial.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_1_5">11000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="0" id="id_10451842_EF3EDCB7-CCDA-4EB3-A876-34C1967DBD21_2_6">256000</us-gaap:InterestExpenseDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_1_13">15255000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:PaidInKindInterest contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_1_6">256000</us-gaap:PaidInKindInterest>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_3_11">-11698000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_3_8">-233000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_3_3">10617000</us-gaap:OperatingExpenses>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_1_10">-8172000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_3_9">-10850000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_3_4">-10617000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_3_10">848000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_1_12">15255000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_D951497C-3F6B-4B65-B129-AD196328B07B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Following is the stock-based compensation expense related to common
 stock options, common stock, restricted common stock and common
 stock warrants:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;252&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;109&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,413&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;407&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;411&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;121&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,880&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;422&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;663&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;230&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,293&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;829&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="pure" decimals="2" id="id_10451842_116526CF-AA57-49F6-9306-767EF0FD37D9_1_3">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="pure" decimals="4" id="id_10451842_116526CF-AA57-49F6-9306-767EF0FD37D9_1_0">0.0247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="shares" decimals="INF" id="id_10451842_1C7720C1-5B64-465A-9064-A98B68D1851E_5001_5">209124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_BF3970BF-26C5-4CCA-A5BB-0F3E4069BA81_1_3">3.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_5CAF3C7D-1D6F-40A5-AEDF-ADA72707B3DB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;September&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;(in thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Legal and accounting fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;790&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued research and development costs and other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;379&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,428&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,475&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,292&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_3_1">5279000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_87F52533-3AE8-449A-99A0-6F7ECF440ABA_5001_5">4.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_87F52533-3AE8-449A-99A0-6F7ECF440ABA_5001_3">5.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_F1F23B0C-EAAA-4D4A-865D-EF5BB4006F37_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Dilutive shares which could exist pursuant to the exercise of
 outstanding stock instruments and which were not included in the
 calculation because their affect would have been anti-dilutive are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;September&amp;#xA0;30,&lt;br /&gt;
 2018&lt;br /&gt;
 (shares)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;September&amp;#xA0;30,&lt;br /&gt;
 2017&lt;br /&gt;
 (shares)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrants to purchase shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,697,026&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,249,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options to purchase shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,764,648&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,656,888&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Shares of common stock issuable upon conversion of preferred
 stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,308,115&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,312,282&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,769,789&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,218,760&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="pure" decimals="2" id="id_10451842_116526CF-AA57-49F6-9306-767EF0FD37D9_1_2">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_73EBD41D-67AD-49F0-AFF0-582E2B986971_3_2">3293000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_116526CF-AA57-49F6-9306-767EF0FD37D9_1_1">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_87F52533-3AE8-449A-99A0-6F7ECF440ABA_5001_4">1.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_F62CC45C-152D-4037-A131-23A4B5FAB75B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the stock option activity in the
 Company&amp;#x2019;s equity incentive plans, including &lt;font style="WHITE-SPACE: nowrap"&gt;non-plan&lt;/font&gt; grants to Company executives,
 from December&amp;#xA0;31, 2017 through&amp;#xA0;September 30, 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,155,263&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,011,875&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.02&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,193,366&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.99&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(209,124&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, September&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,764,648&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_462AA18E-38A6-423A-A42C-0780B450F654_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of all other options granted is determined using the
 Black-Scholes option-pricing model. The following weighted average
 assumptions were used:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Nine&lt;br /&gt;
 Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Nine&lt;br /&gt;
 Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;br /&gt;
 2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.47&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life of the options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.7&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility of the underlying stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;104&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_7DFD73CC-C420-47FF-8D46-017588D7C428_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the common stock warrant activity
 from December&amp;#xA0;31, 2017 through September&amp;#xA0;30, 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,229,778&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.15&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,533,042&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, September&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,697,026&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="shares" decimals="INF" id="id_10451842_1C7720C1-5B64-465A-9064-A98B68D1851E_5001_3">1011875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="shares" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_3_13">38822000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <dei:TradingSymbol contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_D49EEED2-E245-4DBF-99D5-A0DA428BC252_1_0">GALT</dei:TradingSymbol>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_F93BD96C-FF2E-4818-B868-550BCC850FD9_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;8. Common Stock&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;2014 At Market Issuance of Common Stock&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On March&amp;#xA0;30, 2014, the Company entered into an At Market
 Issuance Sales Agreement (the &amp;#x201C;2014 At Market
 Agreement&amp;#x201D;) with a sales agent under which the Company may
 issue and sell shares of its common stock having an aggregate
 offering price of up to $30.0&amp;#xA0;million from time to time
 through the sales agent. Sales of the Company&amp;#x2019;s common stock
 through the sales agent, if any, will be made by any method that is
 deemed an &amp;#x201C;at the market&amp;#x201D; offering as defined by the
 U.S. Securities and Exchange Commission. The Company will pay to
 the sales agent a commission rate equal to 3.0% of the gross
 proceeds from the sale of any shares of common stock sold through
 the sales agent under the 2014 At Market Agreement. During the
 three months ended March&amp;#xA0;31, 2017, the Company issued
 1,496,797 shares of common stock for net proceeds of approximately
 $1,945,000 under the 2014 At Market Agreement. The 2014 At Market
 Agreement expired in March 2017.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;2017 At Market Issuance of Common Stock&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On May&amp;#xA0;19, 2017, the Company entered into an At Market
 Issuance Sales Agreement (the &amp;#x201C;2017 At Market
 Agreement&amp;#x201D;) with a sales agent under which the Company may
 issue and sell shares of its common stock having an aggregate
 offering price of up to $30.0&amp;#xA0;million from time to time
 through the sales agent. Sales of the Company&amp;#x2019;s common stock
 through the sales agent, if any, will be made by any method that is
 deemed an &amp;#x201C;at the market&amp;#x201D; offering as defined by the
 U.S. Securities and Exchange Commission. The Company will pay to
 the sales agent a commission rate equal to 3.0% of the gross
 proceeds from the sale of any shares of common stock sold through
 the sales agent under the 2017 At Market Agreement. During June
 2018, the Company issued 618,614 shares of common stock for net
 proceeds of approximately $5,241,000 under the 2017 At Market
 Agreement. In July 2018, the Company issued 51,100 shares of common
 stock for net proceeds of approximately $362,000 under the 2017 At
 Market Agreement.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;2017 Private Placement&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 On February&amp;#xA0;28, 2017, the Company closed a transaction with
 five individual investors through a private placement of common
 stock and warrants. In total, the Company issued 102,368 shares of
 common stock for proceeds of $200,000. The Company also issued, to
 the five investors, warrants to purchase 76,776 shares of common
 stock at $5.00 per share. The warrants have an expiration date of
 February&amp;#xA0;28, 2024. The exercise price of each warrant is
 adjustable in the event of a stock split or stock combination,
 capital reorganization, merger or similar event. The warrants were
 valued at approximately $101,000 as of the date of issuance, using
 the closing price of $1.86, a life of 7 years, a volatility of 97%
 and a risk-free interest rate of 1.92%. Based upon the
 Company&amp;#x2019;s analysis of the criteria contained in ASC Topic
 &lt;font style="white-space:nowrap"&gt;815-40,&lt;/font&gt; &amp;#x201C;Derivatives
 and Hedging &amp;#x2014; Contracts in Entity&amp;#x2019;s Own Equity&amp;#x201D;
 the Company has determined that warrants issued in connection with
 this financing transaction were not derivative liabilities and
 therefore, were recorded as additional &lt;font style="white-space:nowrap"&gt;paid-in&lt;/font&gt; capital.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Other&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In 2018, the Company entered an agreement with a vendor whereby the
 Company will issue common stock to vendor in lieu of paying in cash
 in amount up to $100,000 for the year. For the nine months ended
 September&amp;#xA0;30, 2018, the Company has issued 2,883 shares of
 common stock and 290 warrants to purchase shares of common stock
 pursuant to this agreement and the value of such shares has been
 recorded as research and development expense.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 For the nine months ended September&amp;#xA0;30, 2018, the Company has
 issued a total of 166,072 shares of common stock for dividends on
 Series&amp;#xA0;A, Series&amp;#xA0;B and Series&amp;#xA0;C Preferred Stock.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="shares" decimals="INF" id="id_10451842_1C7720C1-5B64-465A-9064-A98B68D1851E_5001_4">2193366</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <galt:SupplementalDividendsOnConvertiblePreferredStock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_8455C3DF-E91A-423E-925D-D2B831835A1F_1_18">915000</galt:SupplementalDividendsOnConvertiblePreferredStock>
  <galt:AccruedResearchAndDevelopmentCostsAndOther contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_3E0A4418-7531-4C27-840E-3BE0A93F498B_1_2">379000</galt:AccruedResearchAndDevelopmentCostsAndOther>
  <galt:IssuanceOfWarrantsValue contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" unitRef="iso4217_USD" decimals="0" id="id_10451842_EF3EDCB7-CCDA-4EB3-A876-34C1967DBD21_2_1">696000</galt:IssuanceOfWarrantsValue>
  <galt:StockWarrantsTextBlock contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0" id="id_10451842_AD534A1D-8CBF-404D-82A8-A977D722B38F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;5. Common Stock Warrants&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the common stock warrant activity
 from December&amp;#xA0;31, 2017 through September&amp;#xA0;30, 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="69%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,229,778&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.15&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,533,042&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding, September&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,697,026&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.54&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</galt:StockWarrantsTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1776205x1782641" unitRef="shares" decimals="0" id="id_10451842_22EC2E5D-5234-443A-AD8E-AF0FED173F56_1001_1">3764648</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1776205x1792354" unitRef="shares" decimals="0" id="id_10451842_22EC2E5D-5234-443A-AD8E-AF0FED173F56_2001_2">4308115</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1776205x1795345" unitRef="shares" decimals="0" id="id_10451842_22EC2E5D-5234-443A-AD8E-AF0FED173F56_3001_0">10697026</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <galt:WarrantExpirationDate contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1781320x1923965" id="id_10451842_F0B181C9-BA97-4A36-BA0D-413A148F7ED8_1002_9">2024-02-28</galt:WarrantExpirationDate>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1784168x1782499" unitRef="iso4217_USD" decimals="-3" id="id_10451842_73EBD41D-67AD-49F0-AFF0-582E2B986971_1003_1">1880000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1784168x1792236" unitRef="iso4217_USD" decimals="-3" id="id_10451842_73EBD41D-67AD-49F0-AFF0-582E2B986971_2003_0">1413000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1795345" unitRef="shares" decimals="INF" id="id_10451842_22534239-6A3C-4EE4-BA88-CD6A8020F8AB_5001_5">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1795345" unitRef="pure" decimals="2" id="id_10451842_EF3EDCB7-CCDA-4EB3-A876-34C1967DBD21_1002_4">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1795345" unitRef="pure" decimals="4" id="id_10451842_EF3EDCB7-CCDA-4EB3-A876-34C1967DBD21_1002_5">0.0205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1795345" unitRef="shares" decimals="INF" id="id_10451842_22534239-6A3C-4EE4-BA88-CD6A8020F8AB_5001_3">290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1795345" unitRef="pure" decimals="2" id="id_10451842_EF3EDCB7-CCDA-4EB3-A876-34C1967DBD21_1002_3">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1795345" id="id_10451842_EF3EDCB7-CCDA-4EB3-A876-34C1967DBD21_1002_2">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1795345" unitRef="shares" decimals="INF" id="id_10451842_22534239-6A3C-4EE4-BA88-CD6A8020F8AB_5001_4">2533042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1795345" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_3F938FF9-B8A8-4A83-9B33-0082CBADF506_5001_4">2.50</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1795345" unitRef="iso4217_USD_per_shares" decimals="0" id="id_10451842_3F938FF9-B8A8-4A83-9B33-0082CBADF506_5001_5">0</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1795345" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_3F938FF9-B8A8-4A83-9B33-0082CBADF506_5001_3">5.15</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:CommonStockDividendsShares contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1936092_1794413x1962765" unitRef="shares" decimals="INF" id="id_10451842_91C9D61B-024D-4EF4-9C3B-BA44281C6BEA_1001_2">166072</us-gaap:CommonStockDividendsShares>
  <galt:ClassOfWarrantOrRightIssuedInPeriod contextRef="eol_PE87402---1810-Q0006_STD_273_20180930_0_1794413x1962765" unitRef="shares" decimals="INF" id="id_10451842_91C9D61B-024D-4EF4-9C3B-BA44281C6BEA_2001_3">290</galt:ClassOfWarrantOrRightIssuedInPeriod>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1810-Q0006_STD_30_20180630_0_1794413x1925863" unitRef="iso4217_USD" decimals="0" id="id_10451842_00C0B498-91B5-4107-BCF2-015B4331D332_1002_3">5241000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE87402---1810-Q0006_STD_30_20180630_0_1794413x1925863" unitRef="shares" decimals="INF" id="id_10451842_00C0B498-91B5-4107-BCF2-015B4331D332_1002_2">618614</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="eol_PE87402---1810-Q0006_STD_31_20140131_0_1784583x1960983" unitRef="iso4217_USD" decimals="0" id="id_10451842_D2D946C9-7609-42FB-8998-E61309A66791_2003_0">400000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE87402---1810-Q0006_STD_31_20180131_0" unitRef="shares" decimals="INF" id="id_10451842_BF3970BF-26C5-4CCA-A5BB-0F3E4069BA81_3_4">460000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="eol_PE87402---1810-Q0006_STD_31_20180131_0" unitRef="shares" decimals="INF" id="id_10451842_BF3970BF-26C5-4CCA-A5BB-0F3E4069BA81_3_5">115000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="eol_PE87402---1810-Q0006_STD_31_20180131_0_1794693x1912783" unitRef="shares" decimals="INF" id="id_10451842_BF3970BF-26C5-4CCA-A5BB-0F3E4069BA81_2003_6">345000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1810-Q0006_STD_31_20180731_0_1794413x1925863" unitRef="iso4217_USD" decimals="0" id="id_10451842_00C0B498-91B5-4107-BCF2-015B4331D332_1003_3">362000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE87402---1810-Q0006_STD_31_20180731_0_1794413x1925863" unitRef="shares" decimals="INF" id="id_10451842_00C0B498-91B5-4107-BCF2-015B4331D332_1003_2">51100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <galt:AccruedResearchAndDevelopmentCostsAndOther contextRef="eol_PE87402---1810-Q0006_STD_365_20171231_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_3E0A4418-7531-4C27-840E-3BE0A93F498B_2_2">1428000</galt:AccruedResearchAndDevelopmentCostsAndOther>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1810-Q0006_STD_90_20170331_0_1794413x1949985" unitRef="iso4217_USD" decimals="0" id="id_10451842_8F8FE83D-9633-4D4B-8F94-ECAD8A7A28ED_1002_3">1945000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE87402---1810-Q0006_STD_90_20170331_0_1794413x1949985" unitRef="shares" decimals="INF" id="id_10451842_8F8FE83D-9633-4D4B-8F94-ECAD8A7A28ED_1002_2">1496797</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_90_20180331_0_1777388x1782641" unitRef="iso4217_USD" decimals="0" id="id_10451842_BF3970BF-26C5-4CCA-A5BB-0F3E4069BA81_1004_7">526000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_91_20180630_0_1777388x1782641" unitRef="iso4217_USD" decimals="0" id="id_10451842_BF3970BF-26C5-4CCA-A5BB-0F3E4069BA81_1002_7">433000</us-gaap:ShareBasedCompensation>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_2_12">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_2_2">911000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_2_6">6000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_2_11">-4662000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_2_8">6000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_2_3">4414000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_2_9">-4408000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_2_4">-4414000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_2_10">254000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_2_1">3503000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_73EBD41D-67AD-49F0-AFF0-582E2B986971_2_2">230000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0" unitRef="shares" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_2_13">35165000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0_1784168x1782499" unitRef="iso4217_USD" decimals="-3" id="id_10451842_73EBD41D-67AD-49F0-AFF0-582E2B986971_1002_1">121000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_92_20170930_0_1784168x1792236" unitRef="iso4217_USD" decimals="-3" id="id_10451842_73EBD41D-67AD-49F0-AFF0-582E2B986971_2002_0">109000</us-gaap:ShareBasedCompensation>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_1_12">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_1_2">1175000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_1_6">15000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InterestExpense contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_1_7">87000</us-gaap:InterestExpense>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD" decimals="0" id="id_10451842_EF3EDCB7-CCDA-4EB3-A876-34C1967DBD21_1_6">87000</us-gaap:InterestExpenseDebt>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_1_11">-3046000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_1_8">-72000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_1_3">2680000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_1_9">-2752000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_1_4">-2680000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_1_10">294000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_1_1">1505000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="iso4217_USD" decimals="-3" id="id_10451842_73EBD41D-67AD-49F0-AFF0-582E2B986971_1_2">663000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0" unitRef="shares" decimals="-3" id="id_10451842_B35528A0-ABE2-44C6-A4AF-7D4867AC0BAE_1_13">40921000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0_1779175x1900661_1784583x1960983" unitRef="pure" decimals="3" id="id_10451842_D2D946C9-7609-42FB-8998-E61309A66791_1002_5">0.805</us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0_1784168x1782499" unitRef="iso4217_USD" decimals="-3" id="id_10451842_73EBD41D-67AD-49F0-AFF0-582E2B986971_1001_1">411000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0_1784168x1792236" unitRef="iso4217_USD" decimals="-3" id="id_10451842_73EBD41D-67AD-49F0-AFF0-582E2B986971_2001_0">252000</us-gaap:ShareBasedCompensation>
  <us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates contextRef="eol_PE87402---1810-Q0006_STD_92_20180930_0_1784583x1960983" unitRef="iso4217_USD" decimals="0" id="id_10451842_D2D946C9-7609-42FB-8998-E61309A66791_2002_2">34000</us-gaap:PaymentsToAcquireBusinessesAndInterestInAffiliates>
  <context id="eol_PE87402---1810-Q0006_STD_92_20180930_0_1784583x1960983">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_92_20180930_0_1784168x1792236">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_92_20180930_0_1784168x1782499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_92_20180930_0_1779175x1900661_1784583x1960983">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SbhSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_92_20180930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_92_20170930_0_1784168x1792236">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_92_20170930_0_1784168x1782499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_92_20170930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_91_20180630_0_1777388x1782641">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_90_20180331_0_1777388x1782641">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_90_20170331_0_1794413x1949985">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandFourteenAtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_365_20171231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_31_20180731_0_1794413x1925863">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandSeventeenAtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_31_20180131_0_1794693x1912783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">galt:RemainderOfCurrentYearMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_31_20180131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_31_20140131_0_1784583x1960983">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_30_20180630_0_1794413x1925863">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandSeventeenAtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-06-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20180930_0_1794413x1962765">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:OtherAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1936092_1794413x1962765">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:SeriesAndPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:OtherAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20180930_0_1792342x1795345">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20180930_0_1784168x1792236">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20180930_0_1784168x1782499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20180930_0_1781320x1923965">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">galt:PrivatePlacementTwentySeventeenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20180930_0_1776205x1795345">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20180930_0_1776205x1792354">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20180930_0_1776205x1782641">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20180930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20170930_0_1784168x1792236">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20170930_0_1784168x1782499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20170930_0_1776205x1795345">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20170930_0_1776205x1792354">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20170930_0_1776205x1782641">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_273_20170930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_23_20180531_0_1794693x1912783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">galt:RemainderOfCurrentYearMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-05-09</startDate>
      <endDate>2018-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_23_20180531_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2018-05-09</startDate>
      <endDate>2018-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_1369_20180930_0_1784583x1960983">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_1369_20180930_0_1779175x1900661_1784583x1960983">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SbhSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_1_20170228_0_1781320x1923965_1787544x1788637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">galt:PrivatePlacementTwentySeventeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-02-28</startDate>
      <endDate>2017-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_1_20170228_0_1781320x1923965_1787544x1787543">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">galt:PrivatePlacementTwentySeventeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-02-28</startDate>
      <endDate>2017-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_1_20170228_0_1781320x1923965">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">galt:PrivatePlacementTwentySeventeenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-02-28</startDate>
      <endDate>2017-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20171231_0_1793148x1780634">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792342x1795345">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1962989">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBTwoConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1957907">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBOneConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1953652">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1909376">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBThreeConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20171231_0_1792341x1791539">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20171231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792342x1795345">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1962989">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBTwoConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1957907">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBOneConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1953652">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1909376">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBThreeConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20180930_0_1792341x1791539">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20180930_0_1791654x1929454_1794413x1962765">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:VendorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:OtherAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20180930_0_1791038x1786251_1791654x1929454_1794413x1962765">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">galt:VendorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:OtherAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20180930_0_1784583x1960983">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20180930_0_1779182x1962572_1793148x1780634">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20180930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20170930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20140330_0_1794413x1949985">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandFourteenAtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20181107_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2018-11-07</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20171219_0_1779182x1962572_1793148x1780634">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">galt:UnsecuredLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-19</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20170519_0_1794413x1925863">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:TwoThousandSeventeenAtMarketSalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-05-19</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20170228_0_1781320x1923965_1787544x1787453">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">galt:PrivatePlacementTwentySeventeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-02-28</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20170228_0_1781320x1923965">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">galt:PrivatePlacementTwentySeventeenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-02-28</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20140131_0_1784583x1960983">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1810-Q0006_STD_0_20140131_0_1779175x1900661_1784321x1784953_1784583x1960983">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">galt:GalectinSciencesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">galt:SbhSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-01-31</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
</xbrl>